KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) EBT Margin (2017 - 2025)

Historic EBT Margin for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to 11.23%.

  • Takeda Pharmaceutical's EBT Margin fell 36200.0% to 11.23% in Q4 2025 from the same period last year, while for Dec 2025 it was 23.76%, marking a year-over-year increase of 69700.0%. This contributed to the annual value of 3.82% for FY2025, which is 25800.0% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's EBT Margin stood at 11.23%, which was down 36200.0% from 25.55% recorded in Q3 2025.
  • Takeda Pharmaceutical's EBT Margin's 5-year high stood at 29.19% during Q1 2025, with a 5-year trough of 4.52% in Q1 2024.
  • Over the past 5 years, Takeda Pharmaceutical's median EBT Margin value was 15.42% (recorded in 2022), while the average stood at 16.15%.
  • As far as peak fluctuations go, Takeda Pharmaceutical's EBT Margin plummeted by -192100bps in 2024, and later surged by 337100bps in 2025.
  • Takeda Pharmaceutical's EBT Margin (Quarter) stood at 8.01% in 2021, then rose by 22bps to 9.77% in 2022, then soared by 104bps to 19.97% in 2023, then fell by -26bps to 14.85% in 2024, then decreased by -24bps to 11.23% in 2025.
  • Its last three reported values are 11.23% in Q4 2025, 25.55% for Q3 2025, and 25.14% during Q2 2025.